News

First patient enrolled in Phase II study ADR-02 (AdrenOSS-2), designed to demonstrate safety and efficacy of Adrecizumab in patients with early septic shock Study to be conducted in Germany, the Netherlands, Belgium, and France Population

Comprehensive clinical safety review of Adrecizumab to be presented Opinion leaders will discuss effects of Adrecizumab and its target Adrenomedullin on septic shock mortality in four sessions Adrenomed expects to start enrolment for Phase II

Germany first country to grant full approval for Phase II study ADR-02 (AdrenOSS-2) with Adrecizumab in patients with early septic ADR-02 study to enroll 300 patients in Germany, Belgium, France and the Netherlands for proof

Phase-I study demonstrates excellent tolerability and safety of Adrecizumab in healthy subjects Unique mode of action confirmed in humans  Phase-II study in septic shock is on the way Adrenomed plans additional Phase-II study in acute